KPV is a three-amino-acid peptide
The letters K-P-V correspond to lysine, proline, and valine. Scientific publications describe KPV as a short sequence associated with the C-terminal region of alpha-melanocyte-stimulating hormone.
That identity helps organize the research, but it does not tell you the concentration, stability, carrier, skin delivery, safety, or performance of a finished formula.
Sources for this section: KPV signaling in human keratinocyte models
What kinds of KPV evidence are available?
| Research type | Question studied | Product relevance |
|---|---|---|
| Cultured keratinocytes | Cell signaling under controlled laboratory conditions | Mechanistic context, not proof of a cosmetic or medical outcome |
| Prepared human-skin diffusion model | Movement with microneedles, iontophoresis, or both | Delivery-method evidence, not ordinary topical use |
| Stability-indicating laboratory assay | Measurement of KPV and degradation products | Analytical method evidence, not finished-product shelf life or efficacy |
| Controlled finished-product human trial | Safety and outcomes for the exact topical formula | No comparable trial was identified for VitaPep KPV Serum |
What the skin-delivery study actually tested
A 2017 laboratory study measured KPV movement across dermatomed human skin. Passive diffusion was below the study’s detection limit. Delivery increased when the researchers used microneedles, iontophoresis, or both.
Those physical enhancement methods are not the same as applying VitaPep KPV Serum to intact external skin. The study therefore illustrates why route and method matter; it does not quantify delivery from VitaPep’s DMSO-based finished formula.
Sources for this section: KPV delivery across microporated human skin (PubMed)
What the stability study does—and does not—show
A 2015 study validated an HPLC method for measuring KPV in aqueous solutions and skin homogenates and separating it from degradation products formed under stress conditions.
That supports laboratory measurement of KPV. It does not establish the shelf life, storage limits, skin delivery, safety, or visible results of a different commercial formula unless the finished product is studied directly.
Sources for this section: KPV stability-indicating HPLC assay (PubMed)
What applies to VitaPep KPV Serum?
- The product label lists 10 mg of KPV in a 30 mL bottle.
- A submitted-liquid concentration assessment for batch KPV020 reported 0.34 mg/mL, equivalent to 10.2 mg across 30 mL for that submitted sample. No separate finished-serum microbiological or heavy-metal report was verified.
- The listed carrier is 70% DMSO and 30% deionized water.
- The formula is ready to use on external skin according to the current packaging.
- VitaPep does not present the product as an injectable or as a treatment for inflammation, wounds, or disease.
What should a careful KPV claim include?
- The exact KPV form, concentration, carrier, and application route.
- Whether the evidence comes from cells, prepared skin, animals, or people.
- Whether a delivery study used microneedles, current, damaged skin, or another special method.
- Whether the tested formula matches the product being sold.
- A clear separation between research interest and established finished-product outcomes.
Continue your research
Selected authoritative sources
These sources are provided so you can inspect the study type, molecule, route, and limitations directly. They do not endorse a VitaPep product.